Testing SGLT2 Inhibitors for Heart Health in Hypertension
Part of Heart & circulation clinical trials.
This trial tests whether an SGLT2 inhibitor (a type of diabetes drug) can help prevent heart attacks, strokes, and other heart problems in people with high blood pressure. You may be eligible if you are 60 or older, have high blood pressure, and have had a heart or blood vessel event (like a heart attack or stroke) or have certain risk factors (like smoking, high cholesterol, or obesity).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 60 years old or older.
- You must have high blood pressure (either newly diagnosed with readings above 140/90, or already diagnosed).
- You must have had at least one heart or blood vessel event (like a heart attack, stroke, or blocked leg arteries) OR have at least one risk factor (like smoking, high cholesterol, being 75 or older, a high heart risk score, or a BMI over 32).
- You cannot have a history of diabetes or diabetic ketoacidosis.
- You cannot have had a heart attack or stroke in the last 3 months.
- You cannot have symptomatic heart failure or severely reduced kidney function (eGFR below 25).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a medicine (SGLT2 inhibitor) given to people with high blood pressure and early signs of heart stress can help prevent heart failure. You may join if your blood pressure is controlled but tests show your heart is beginning to struggle.
This study tests whether a medication called an SGLT2 inhibitor (a type of diabetes drug) can improve the function of the upper left heart chamber in people who have paroxysmal atrial fibrillation, high blood pressure, and abnormal blood sugar levels. If you qualify, the trial may help your heart work better and reduce your risk of stroke.
This study tests whether a type of diabetes medication called an SGLT2 inhibitor can improve the structure and function of the heart's left atrium in people with type 2 diabetes. It may help prevent heart problems in the future.
This study tests whether a heart medication (SGLT2 inhibitor) affects fat around the heart's arteries in people who have had a heart attack but do not have diabetes or heart failure. It uses a CT scan to measure changes over time.
This trial tests whether an SGLT2 inhibitor pill can help people who have atrial fibrillation (an irregular heartbeat) and type 2 diabetes. You may be eligible if you’re in the right age range, on diabetes pills only, and meet specific heart and lab criteria.
This study tests whether diabetes medicines can help prevent worsening heart and kidney problems in people with type 2 diabetes. You’ll be assigned by chance to one of these medicine types, and your other care will be adjusted for safety.
Hear when a new Atrial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.